Exploring Medication Nonadherence in Specialty Therapy

In an interview with Pharmacy Times at Asembia’s AXS26 Summit, Michael Oleksiw, CEO of Pleio addressed the challenge of medication nonadherence in specialty therapy, where nearly half of all treatment failures are tied to adherence issues. Mechanical interventions like push notifications alone fall short; overcoming nonadherence in specialty therapies requires AI-driven insights paired with human-centered outreach to tackle the emotional and psychological barriers patients face. Oleksiw highlighted GLP-1 medications as a prime example, where stigma, dose escalation, and recurring emotional hurdles make specialty therapy adherence especially difficult to sustain.